KemPharm Inc. (NASDAQ:KMPH) shot up 5.9% during mid-day trading on Thursday . The stock traded as high as $4.58 and last traded at $4.48, with a volume of 58,153 shares changing hands. The stock had previously closed at $4.23.

Several research firms have issued reports on KMPH. Canaccord Genuity reissued a “buy” rating on shares of KemPharm in a research report on Tuesday, May 3rd. Royal Bank Of Canada lowered their price objective on shares of KemPharm from $22.00 to $14.00 and set an “outperform” rating for the company in a research report on Friday, May 6th. Zacks Investment Research cut shares of KemPharm from a “hold” rating to a “sell” rating in a research report on Wednesday, May 4th. Finally, Oppenheimer Holdings Inc. reissued a “buy” rating on shares of KemPharm in a research report on Wednesday, June 8th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $26.80.

The company’s 50 day moving average is $4.78 and its 200-day moving average is $11.73. The firm’s market capitalization is $64.28 million.

KemPharm (NASDAQ:KMPH) last issued its earnings results on Thursday, May 12th. The specialty pharmaceutical company reported ($0.20) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.46) by $0.26. Equities research analysts expect that KemPharm Inc. will post ($2.79) earnings per share for the current year.

KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. It uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs by chemically attaching one or more molecules, referred to as ligands, to the parent drug.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.